Cancer risk in long-term users of vitamin K antagonists: A population-based case-control study

International Journal of Cancer

Volumn 132, Issue 11, 2013, Pages 2606-2612

  Pottegård, Anton ^a   Friis, Søren ^b   Hallas, Jesper ^a  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

cancer; case control study; pharmacoepidemiology; population based; vitamin K antagonists

Indexed keywords

ANTIVITAMIN K; DIGOXIN; PHENPROCOUMON; VERAPAMIL; WARFARIN;

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM EXPOSURE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; OBESITY; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; URINARY TRACT CANCER; VENOUS THROMBOEMBOLISM;

AGED; ANTICOAGULANTS; CASE-CONTROL STUDIES; DENMARK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; RISK FACTORS; VITAMIN K;

EID: 84875616913     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27905     Document Type: Article

References (41)

1. Lyman GH,. Venous thromboembolism in the patient with cancer: focus on burden of disease and benefits of thromboprophylaxis. Cancer 2011; 117: 1334-49.
2. Akl EA, Labedi N, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2011; CD006650.
3. Rickles FR, Levine MN,. Venous thromboembolism in malignancy and malignancy in venous thromboembolism. Haemostasis 1998; 28 (Suppl 3): 43-9.
4. Sorensen HT, Mellemkjaer L, Steffensen FH, et al. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-73.
5. Baron JA, Gridley G, Weiderpass E, et al. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-80.
6. Nordstrom M, Lindblad B, Anderson H, et al. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 1994; 308: 891-4.
7. Gay LJ, Felding-Habermann B,. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011; 11: 123-34.
8. Jain S, Harris J, Ware J,. Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol 2010; 30: 2362-7.
9. van Sluis GL, Buller HR, Spek CA,. The role of activated protein C in cancer progression. Thromb Res 2010; 125 (Suppl 2): S138-S142.
10. Smorenburg SM, Van Noorden CJ,. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53: 93-105.
11. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study #75. Cancer 1984; 53: 2046-52.
12. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75. JAMA 1981; 245: 831-5.
13. Maurer LH, Herndon JE, Hollis DR, et al. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. J Clin Oncol 1997; 15: 3378-87.
14. Pengo V, Denas G, Jose SP, et al. Cancer prevention and vitamin K antagonists: an overview. Thromb Res 2010; 125 (Suppl 2): S103-S105.
15. Akl EA, Vasireddi SR, Gunukula S, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database Syst Rev 2011; CD006466.
16. Schulman S, Rhedin AS, Lindmarker P, et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995; 332: 1661-5.
17. Schulman S, Lindmarker P,. Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of anticoagulation trial. N Engl J Med 2000; 342: 1953-8.
18. Taliani MR, Agnelli G, Prandoni P, et al. Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost 2003; 1: 1730-3.
19. Blumentals WA, Foulis PR, Schwartz SW, et al. Does warfarin therapy influence the risk of bladder cancer? Thromb Haemost 2004; 91: 801-5.
20. Tagalakis V, Tamim H, Blostein M, et al. Use of warfarin and risk of urogenital cancer: a population-based, nested case-control study. Lancet Oncol 2007; 8: 395-402.
21. Pengo V, Noventa F, Denas G, et al. Long-term use of vitamin K antagonists and incidence of cancer: a population-based study. Blood 2011; 117: 1707-9.
22. Ahern TP, Pedersen L, Svaerke C, et al. The association between vitamin K antagonist therapy and site-specific cancer incidence estimated by using heart valve replacement as an instrumental variable. Am J Epidemiol 2011; 174: 1382-90.
23. Storm HH, Michelsen EV, Clemmensen IH, et al. The Danish Cancer Registry-history, content, quality and use. Dan Med Bull 1997; 44: 535-9.
24. Gjerstorff ML,. The Danish Cancer Registry. Scand J Public Health 2011; 39: 42-5.
25. Jensen AR, Overgaard J, Storm HH,. Validity of breast cancer in the Danish Cancer Registry. A study based on clinical records from one county in Denmark. Eur J Cancer Prev 2002; 11: 359-64.
26. Lynge E, Sandegaard JL, Rebolj M,. The Danish National Patient Register. Scand J Public Health 2011; 39: 30-3.
27. Kildemoes HW, Sorensen HT, Hallas J,. The Danish National Prescription Registry. Scand J Public Health 2011; 39: 38-41.
28. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment 2011. Oslo: WHO Collaborating Centre for Drug Statistics Methodology, 2010.
29. Pedersen CB,. The Danish Civil Registration System. Scand J Public Health 2011; 39: 22-5.
30. Rothman KJ, Greenland S, Lash TL,. Modern epidemiology, 3rd edn. Philadelphia: Wolters Kluwer Health, Lippincott Williams & Wilkins, 2008.
31. Csizmadl I, Collet J-P, Boivin J,. Bias and confounding in pharmacoepidemiology. In:, Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: Wilay and Sons, 2007. 791-810.
32. Hallas J, Gaist D, Bjerrum L,. The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology 1997; 8: 666-70.
33. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
34. Thygesen SK, Christiansen CF, Christensen S, et al. The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients. BMC Med Res Methodol 2011; 11: 83.
35. Secretan B, Straif K, Baan R, et al. A review of human carcinogens-Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009; 10: 1033-4.
36. Baan R, Straif K, Grosse Y, et al. Carcinogenicity of alcoholic beverages. Lancet Oncol 2007; 8: 292-3.
37. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity and the prevention of cancer: a global perspective. Washington, DC: AICR, 2007.
38. Lægemiddelstyrelsen. Medstat.dk. Available at: http://www.medstat. dk [Last updated 25/5/2011; citeret 5/6/2011].
39. Ewertz M, Mellemkjaer L, Poulsen AH, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005; 92: 1293-7.
40. Glynn RJ, Knight EL, Levin R, et al. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 2001; 12: 682-9.
41. Allman-Farinelli MA,. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011; 37: 903-7.